NCT00509223

Brief Summary

Obstructive Sleep Apnea (OSA) and type 2 diabetes mellitus are two prevalent medical conditions with significant associated cardiovascular and cerebrovascular morbidity and mortality. Research indicates that the prevalence of OSA is increased in diabetic patients when compared with normoglycemic patients and that OSA is independently associated with type 2 diabetes. Further research suggests that effective treatment of the OSA with continuous positive airway pressure (CPAP) improves insulin responsiveness in both non-diabetic OSA patients and diabetic-OSA patients. We are proposing a clinical trial to evaluate the impact of 6 months of CPAP therapy on glycemic control in type 2 diabetic patients with OSA. The primary objective of this study is to assess the effectiveness of CPAP in improving glycemic control (HbA1c) in type 2 diabetic patients with newly diagnosed OSA. Secondary objectives of this study include: assessment of fasting and post prandial glucose, determination as to whether there are any biochemical markers for OSA in the type 2 diabetic population; assessment of any improvements in cardiovascular outcomes; evaluation of any improvement in quality of life. Patients with OSA will be randomized into one of two groups: either a CPAP treatment group or a non-treatment group. Patients will be followed at 3 months and 6 months with collection of various lab tests to assess glycemic control.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
416

participants targeted

Target at P75+ for not_applicable diabetes-mellitus-type-2

Timeline
Completed

Started Jul 2007

Longer than P75 for not_applicable diabetes-mellitus-type-2

Geographic Reach
3 countries

15 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2007

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

July 29, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 31, 2007

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2012

Completed
1.7 years until next milestone

Results Posted

Study results publicly available

October 17, 2013

Completed
Last Updated

December 30, 2013

Status Verified

December 1, 2013

Enrollment Period

4.6 years

First QC Date

July 29, 2007

Results QC Date

August 8, 2013

Last Update Submit

December 4, 2013

Conditions

Keywords

Type 2 diabetesObstructive sleep apneaGlycemic controlInsulin resistanceSleep disordered breathing

Outcome Measures

Primary Outcomes (1)

  • HbA1c Change

    Month 6 change in HbA1c (%)

    Baseline to Month 6

Study Arms (2)

Group 1

EXPERIMENTAL

Lifestyle counseling with Positive Airway Pressure (PAP) therapy

Device: Positive Airway Pressure therapyBehavioral: Lifestyle counseling

Group 2

ACTIVE COMPARATOR

Lifestyle counseling without Positive Airway Pressure (PAP) therapy

Behavioral: Lifestyle counseling

Interventions

Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.

Also known as: ResMed AutoSet S8
Group 1

Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.

Group 1Group 2

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age or older,
  • Known diagnosis of type 2 diabetes for at least 3 months
  • HbA1c \>6.5% and \</= 8.5%
  • BMI \</= 40 kg/m2

You may not qualify if:

  • Requires oxygen therapy
  • OSA is severe (AHI\>70 or SaO2\<70%)
  • Work in transport related industries
  • Previous diagnosis of OSA
  • Known MVA due to sleepiness in the previous 5 years
  • Insulin-requiring
  • Use of GLP-1 mimetic (e.g. Byetta) for \< 6 months or \> 6 months but weight not stable
  • Unstable angina

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (15)

Mission Internal Medical Group

Mission Viejo, California, 92691, United States

Location

Advanced Metabolic Care and Research Institute

Temecula, California, 92951, United States

Location

Clinical Research of South Florida

Coral Gables, Florida, 33134, United States

Location

SleepMed of Central Georgia

Macon, Georgia, 31201, United States

Location

Johns Hopkins University

Baltimore, Maryland, 21224, United States

Location

International Diabetes Center

Saint Louis Park, Minnesota, 55416, United States

Location

Rochester Clinical Research

Rochester, New York, 14609, United States

Location

OSU Sleep Medicine Program

Columbus, Ohio, 43210, United States

Location

SleepMed of West Ashley

Charleston, South Carolina, 29407, United States

Location

SleepMed of South Carolina

Columbia, South Carolina, 29201, United States

Location

Cetero Research

San Antonio, Texas, 78229, United States

Location

Royal North Shore Hospital

Sydney, New South Wales, 2065, Australia

Location

Eastern Clinical Research Unit

Box Hill, Victoria, 3128, Australia

Location

Baker IDI Heart and Diabetes Institute

Melbourne, Victoria, 3004, Australia

Location

IUCPQ

Québec, Quebec, G1V 4G5, Canada

Location

Related Publications (1)

  • Shaw JE, Punjabi NM, Naughton MT, Willes L, Bergenstal RM, Cistulli PA, Fulcher GR, Richards GN, Zimmet PZ. The Effect of Treatment of Obstructive Sleep Apnea on Glycemic Control in Type 2 Diabetes. Am J Respir Crit Care Med. 2016 Aug 15;194(4):486-92. doi: 10.1164/rccm.201511-2260OC.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2Sleep Apnea, ObstructiveInsulin ResistanceSleep Apnea Syndromes

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesApneaRespiration DisordersRespiratory Tract DiseasesSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesHyperinsulinism

Results Point of Contact

Title
Jonathan Shaw, MD, FRACP, FRCP
Organization
Baker IDI Heart and Diabetes Institute

Study Officials

  • Paul Zimmet, MBBS MD PhD

    International Diabetes Institute, Australia

    STUDY CHAIR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 29, 2007

First Posted

July 31, 2007

Study Start

July 1, 2007

Primary Completion

February 1, 2012

Study Completion

February 1, 2012

Last Updated

December 30, 2013

Results First Posted

October 17, 2013

Record last verified: 2013-12

Locations